SCHEMBL2763159

SCHEMBL2763159

CCCc1ccc(S(=O)(=O)Nc2nc(-c3ccc(NC(C)=O)cc3)cs2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.71
ALDH1A1 P00352 5/20 0.59
KMT2A Q03164 7/20 0.58
MEN1 O00255 6/20 0.58
RAB9A P51151 3/20 0.58
NPC1 O15118 2/20 0.58
POLB P06746 1/20 0.58
GAA P10253 2/20 0.55
GFER P55789 1/20 0.55
LMNA P02545 3/20 0.54
PKM P14618 1/20 0.54
KDM1A O60341 2/20 0.54
ADRB3 P13945 2/20 0.53
ADRB2 P07550 1/20 0.52
ADRB1 P08588 1/20 0.52
AKT1 P31749 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
NPSR1 Q6W5P4 1/20 0.52
MAOA P21397 1/20 0.52
MAPK1 P28482 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2762864 0.85 MAPT (0.77) MAPTALDH1A1KMT2AMEN1RAB9A
SCHEMBL2762877 0.84 MEN1 (0.72) MAPTKMT2AMEN1POLBLMNA
SCHEMBL15113217 0.83 MAPT (0.74) MAPTALDH1A1KMT2AMEN1RAB9A
SCHEMBL5832153 0.82 AKT1 (0.65) MAPTALDH1A1KMT2AMEN1GAA
SCHEMBL2762943 0.82 KDM1A (0.72) MAPTALDH1A1KMT2AMEN1RAB9A
SCHEMBL16607133 0.82 KMT2A (0.64) MAPTALDH1A1KMT2AMEN1RAB9A
SCHEMBL5832283 0.82 AKT1 (0.51) MAPTALDH1A1KMT2AMEN1RAB9A
SCHEMBL6612133 0.79 POLB (0.49) MAPTALDH1A1KMT2AMEN1POLB
SCHEMBL2762866 0.78 MEN1 (0.57) MAPTALDH1A1KMT2AMEN1RAB9A
SCHEMBL2762303 0.78 NPSR1 (0.57) ALDH1A1KMT2AMEN1RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7132436-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-11-07 US claimed
WO-2004112783-A1 NEW USE IV BIOVITRUM AB (SE) 2004-12-29 WO claimed
US-20030166689-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 CLARIO TECH LIMITED (GB) 2003-09-04 US claimed
EP-1283832-B1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2010-10-20 EP disclosed
US-7132436-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-11-07 US disclosed
WO-2004112783-A1 NEW USE IV BIOVITRUM AB (SE) 2004-12-29 WO disclosed
US-20030166689-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 CLARIO TECH LIMITED (GB) 2003-09-04 US disclosed
EP-1283832-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-02-19 EP disclosed
WO-2001090092-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166689-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 MAPT 3275/4885ALDH1A1 55/4885KMT2A 3304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.